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Abstract 
  
High dose steroids (HDS) are used in the treatment of haematological malignancies. The 
reported risk of steroid-induced diabetes (SID) is high. However, screening is not consistently 
performed. We implemented a protocol for detection and management of SID and steroid-
induced hyperglycamia (SIH) in haematology outpatients receiving HDS.  
Eighty-three  people were diagnosed with a lymphoproliferative disorder, of whom 6 had 
known Type 2 diabetes. Fifty-three people without known diabetes were screened by HbA1c 
and random venous plasma glucose. All patients (n=34) subsequently prescribed HDS 
checked capillary blood glucose (CBG) pre-breakfast and pre-evening meal. Treatment 
algorithms used initiation and/or dose titration of gliclazide or human NPH insulin, aiming 
for pre-meal CBG 5-11mmol/l. Type 2 diabetes was identified in 4/53 people screened 
(7.5%).  Of 34 people treated with HDS, 17 (44%) developed SIH/SID.  All 7 people with 
Type 2 diabetes developed SIH and 3 required insulin. Of 27 people without known diabetes, 
8 (30%) developed SID and 1 required insulin.  Pre-treatment HbA1c was higher in people 
who developed SID compared to those that did not (p=0.002).  This is the first report of a 
SID/SIH detection and treatment protocol for use in people with lymphoproliferative 
disorders receiving intermittent HDS, demonstrating its feasibility and safety.   
 
Introduction 
High dose steroids (HDS) are commonly used in the treatment of haematological disorders. 
SID, in people without pre-existing diabetes, and steroid-induced hyperglycaemia (SIH), in 
people with diabetes, are recognised as important complications of steroid treatment (1, 2) 
(3). The incidence of SID in people with haematological malignancies is likely to be under-
estimated, however, case series suggests the incidence is as high as 40% (4, 5). We designed 
and piloted a  protocol for the detection and management of SIH/SID in haematology 
outpatients.  
 
Methods 
The full protocol is available in supplementary data and was piloted between November 2013 
and November 2014.  Patients diagnosed with a lymphoproliferative disorder, and not known 
to have diabetes, were screened for diabetes using the WHO diagnostic criteria (6).   
 
  
In people requiring HDS, the protocol recommended referral to the diabetes team prior to 
commencement for those with: Type 1 diabetes, ketosis prone Type 2 diabetes, new diagnosis 
of diabetes, known diabetes with  HbA1c ≥8.0% (64 mmol/mol), or on basal bolus insulin 
regimen, GLP-1 receptor agonist, or pioglitazone or an eGFR <45 ml/min. People without 
known diabetes and people with known Type 2 diabetes not meeting the criteria above were 
managed by the haematology team using a series of algorithms.  
 
For those not on a sulphonylurea or insulin, treatment algorithms were based on starting 
gliclazide or human NPH insulin (Humulin I). People with capillary blood glucose (CBG) 
>18mmol/l, and those already on gliclazide 160 mg bd, were started on insulin. Doses were 
titrated with a target CBG 5-11 mmol/l. At the end of the HDS the gliclazide and/or insulin 
was stopped and people were advised to continue monitoring. The algorithm for those already 
on gliclazide used similar parameters, but titration rather than commencement of gliclazide.  
 
Patient feedback was sought. A student’s t-test was used to compare parameters. A p value 
<0.05 was considered statistically significant.  
 
Results 
Eighty-three people were diagnosed with a lymphoproliferative disorder during the pilot and 
59 (71%) had an HbA1c measured. Six (7%) had pre-existing diabetes (all Type 2 diabetes). 
Four of 53 (7.5%) people without known diabetes were found to have Type 2 diabetes. 
Thirty-four patients received treatment with HDS as part of their chemotherapy regimen. 
Patient characteristics are given in table 1. Fifteen (44%) developed SIH/SID requiring 
treatment.  
Of the 34 patients treated with HDS, 7 (20%) had Type 2 diabetes, one identified by 
screening. Prior to HDS, all were treated with diet or oral agents, including 3 people on 
gliclazide. The mean HbA1c was 7.1% (54 mmol/mol), range 6.1-8.2% (43-66 mmol/l). All 
those with pre-existing diabetes developed SIH requiring a change of treatment. Of 2 people 
on diet alone, 1 required gliclazide and 1 declined treatment for hyperglycaemia.  Of 2 people 
on non-sulphonylurea oral hypoglycaemic agents (OHAs), 1 required gliclazide and the other 
was initally managed with gliclazide and then required insulin on a later course (Figure 1). Of 
3 people on OHAs including gliclazide, 1 was managed with dose titration and 2 required 
insulin. 
  
Twenty-seven of the 34 people treated with HDS did not have known diabetes and 8 (30%) 
developed SID. Two of  8 did not have SID during their first HDS course and developed it on 
subsequent courses. The mean HbA1c prior to HDS in those that developed SID was 
significantly higher than those who did not (p=0.002). There was no significant difference in 
BMI. Four of 9 (44%) patients of African/Caribbean descent developed SID. Seven of 8 
patients were managed with gliclazide. One patient receiving high doses of 
methylprednisolone (1mg/kg/day) required insulin.  
There were no hyperglycaemia-related hospital admissions and no episodes of 
hypoglycaemia reported.  
Seven patients completed a feedback questionnaire. Their overall confidence in the protocol 
and testing CBG was scored as an 8/10 (with 0 being not confident at all and 10 being most 
confident).  
Discussion 
In this pilot in people with lymphoproliferative disorders requiring short courses of HDS we 
found an overall incidence of SID/SIH of 44%. All people with known type 2 diabetes 
developed SIH requiring medication change. The finding of a progressive impact on 
glycaemia with successive steroid courses has previously been reported, highlighting the 
importance of continued monitoring (7). In people without diabetes, 30% developed SID.  
Our population may have been at increased risk with 26% being of Black African or 
Caribbean ethnicity, a mean age of 58.6 years and a mean BMI of 27.7 kg/m
2
. In addition, the 
steroid doses were high, a factor directly correlated with risk of SID (8, 9). However this is 
similar to the incidence of SID in people with haematological malignancies reported 
previously (4, 5, 9, 10).  
 
We identified undiagnosed Type 2 diabetes in 7.5% of those screened. Given that all people 
with pre-existing diabetes treated with HDS developed SIH requiring treatment, we suggest 
screening for undiagnosed diabetes in patients starting HDS. 
 
Our protocol aligns with the JBDS-IP guidelines recommending treatment if CBG ≥11.1 
mmol with a target of 5-11mmol/l compared to the JBDS-IP of recommending treatment if 
CBG >12 mmol/l with a desired target of 6-10 mmol/l and the use of gliclazide or human 
NPH insulin (1).  However, we initiated gliclazide at 80 mg (rather than the 40 mg) and 
  
recommended starting insulin directly at CBG above 18 mmol/l.  Our protocol appears to be 
safe with no episodes of hypoglycaemia and no hospital admissions.  
 
The adverse consequences of SIH/SID are increasingly being recognised in both the inpatient 
and outpatient setting. These include adverse effects on cardiovascular health, increase in 
infectious complications, increase in length of hospital stay and a negative impact on 
outcomes following solid organ transplantation (11). Consequently, there are published 
recommendations for the early detection and prevention of SIH/SID. Most management 
algorithms are similar to our protocol although there are alternative oral agents that may 
provide similar efficacy to gliclazide for those with mild to moderate elevations in blood 
glucose (11, 12).  
 
The importance of interventions to manage symptomatic SID/SIH and prevent hospital 
admissions seems self-evident.  However, whether  short episodes of asymptomatic SID/SIH 
in patients with haematological malignancies are clinically relevant is not known.  A large 
review of  patients requiring treatment for myeloma reported that patients with diabetes or 
SID had a significantly lower overall survival (4). A study of SID in patients with acute 
lymphoblastic leukaemia found that those that developed hyperglycaemia had a shorter 
survival and an increase in infective complications (10). Whether intervention impacts 
outcome is not known.    
 
This is the first report of a SID/SIH detection and treatment protocol for use by haematology 
staff specifically for people with lymphoproliferative disorders receiving  intermittent high 
doses of steroids and demonstrates its feasibility and safety.  
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Table 1: Patient characteristics 
Patients N = 34 (%) 
Mean age (yrs) 58.6 (22 – 87) 
Men 21 (62) 
Ethnicity 
       White       
       Black african/caribbean 
       Other 
 
23 (68) 
9 (26) 
2 
Mean HbA1c in patients without diabetes (n=21) 
mmol/mol % (range) 
41; 5.9 (30-66) 
HbA1c in patients with diabetes (n=6) 
mmol/mol; % (range) 
54; 7.1 (43-66) 
Mean BMI 27.7 (19 – 43.6) 
Known type 2 diabetes 
Non-diabetic 
Screen-detected diabetes 
6 (18) 
27 (79) 
1 
Diagnosis 
       B-cell lymphoma 
       Acute lymphoblastic leukaemia 
       Hodgkin lymphoma 
       T-cell lymphoma 
 
25 
4 
4 
1 
Steroid regimen as part of the chemotherapy, once daily 
 Prednisolone 100mg daily for 5 days repeated  
      every 21 days  
 Prednisolone 60mg/m2 daily for 15 days and  
       repeated every 28 days 
 Dexamethasone 6mg/m2 for 4 days repeated 
every 2  weeks  
 Prednisolone 1mg/kg for 2 weeks 
 Dexamethasone 8mg, then reducing dose 
 Methylprednisolone 1mg/kg for 5 days 
repeated every 28 days 
 Prednisolone 40mg, then reducing by 10mg 
weekly         
 
20 
 
3 
 
3 
 
5 
1 
1 
 
1 
Mean steroid dose, prednisolone equivalent in mg  155 (30– 2500) 
 
 
 
 
 
 
 
 
 
 
  
Figure 1 Flowchart showing patient selection for pilot study 
 
 
 
 
 
 
 
 
 
Figure 2. Capillary blood glucose before breakfast (A) and before evening meal (B) for one 
person over five cycles of HDS.  We have chosen to present this patient because he had good 
glycaemic control before HDS and required gliclazide and then insulin.  Prior to HDS he had 
type 2 diabetes treated with sitagliptin 100mg od only with HbA1c 43 mmol/mol (6.1%) and 
was not monitoring CBG.  He received prednisolone 100mg om for 5 days every 21 days for 
5 cycles. Cycle 1: no change in glucose lowering therapy (team not informed of CBG 
readings); cycle 2: gliclazide 80 mg om started on day 1; cycle 3: gliclazide 80mg om started 
on day 1, increased to 160 mg om and 80 mg pm by day 5; cycle 4: used gliclazide regimen 
from previous cycle; cycle 5: started bd humulin I on day 1. Although target CBG were not 
achieved, the protocol attenuated the marked increase in CBG from day 1 to day 5 seen in 
cycle 1, he did not require hospital admission and there was no hypoglycaemia.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
